Wird geladen...
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
PURPOSE: The combination of an mTOR inhibitor with 5-fluorouracil-based anticancer therapy is attractive because of preclinical evidence of synergy between these drugs. According to our phase I study, the combination of capecitabine and everolimus is safe and feasible, with potential activity in pan...
Gespeichert in:
| Veröffentlicht in: | Cancer Chemother Pharmacol |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer Berlin Heidelberg
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4441736/ https://ncbi.nlm.nih.gov/pubmed/25822310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2730-y |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|